PT  - JOURNAL ARTICLE
AU  - Li, Yihao
AU  - Kronenberg, Florian
AU  - Coassin, Stefan
AU  - Vardarajan, Badri
AU  - Reyes-Soffer, Gissette
TI  - Ancestry specific distribution of LPA Kringle IV-Type-2 genetic variants highlight associations to apo(a) copy number, glucose, and hypertension
AID  - 10.1101/2024.07.09.24310176
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.07.09.24310176
4099  - http://medrxiv.org/content/early/2024/07/10/2024.07.09.24310176.short
4100  - http://medrxiv.org/content/early/2024/07/10/2024.07.09.24310176.full
AB  - Background High Lp(a) levels contribute to atherosclerotic cardiovascular disease and are tightly regulated by the LPA gene. Lp(a) levels have an inverse correlation with LPA Kringle IV Type-2 (KIV-2) copy number (CN). Black (B) and Hispanic (H) individuals exhibit higher levels of Lp(a), and rates of CVD compared to non-Hispanic Whites (NHW). Therefore, we investigated genetic variations in the LPA KIV-2 region across three ancestries and their associations with metabolic risk factors.Methods Using published pipelines, we analyzed a multi-ethnic whole exome dataset comprising 3,817 participants from the Washington Heights and Inwood Columbia Aging Project (WHICAP): 886 [NHW (23%), 1,811 Caribbean (C) H (47%), and 1,120 B individuals (29%). Rare and common variants (alternative allele carrier frequency, CF < 0.01 or > 0.99 and 0.01 < CF < 0.99, respectively) were identified and KIV-2 CN estimated. The associations of variants and CN with history of heart disease, hypertension (HTN), stroke, lipid levels and clinical diagnosis of Alzheimer’s disease (AD) was assessed. A small pilot provided in-silico validation of study findings.Results We report 1421 variants in the LPA KIV-2 repeat region, comprising 267 exonic and 1154 intronic variants. 61.4% of the exonic variants have not been previously described. Three novel exonic variants significantly increase the risk of HTN across all ethnic groups: 4785-C/A (frequency = 78%, odds ratio [OR] = 1.45, p = 0.032), 727-T/C (frequency = 96%, OR = 2.11, p = 0.032), and 723-A/G (frequency = 96%, OR = 1.97, p = 0.038). Additionally, six intronic variants showed associations with HTN: 166-G/A, 387-G/C, 402-G/A, 4527-A/T, 4541-G/A, and 4653-A/T. One intronic variant, 412-C/T, was associated with decreased blood glucose levels (frequency = 72%, β = −14.52, p = 0.02).Three of the associations were not affected after adjusting for LPA KIV-2 CN: 412-C/T (β = −14.2, p = 0.03), 166-G/A (OR = 1.41, p = 0.05), and 387-G/C (OR = 1.40, p = 0.05). KIV CN itself was significantly associated with 314 variants and was negatively correlated with plasma total cholesterol levels.Conclusions In three ancestry groups, we identify novel rare and common LPA KIV-2 region variants. We report new associations of variants with HTN and Glucose levels. These results underscore the genetic complexity of the LPA KIV-2 region in influencing cardiovascular and metabolic health, suggesting potential genetic regulation of pathways that can be studied for research and therapeutic interventions.Clinical PerspectiveLp(a) levels are mostly controlled by the LPA gene and are higher in Blacks and Hispanics.Novel LPA KIV-2 variants found in three ancestry groups, including data on Caribbean Hispanics, show strong positive associations to hypertension and negative associations to glucose levels.Further characterization of these variants and identifying links to disease can help precision medicine efforts to understand disease mechanisms in all populations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Columbia University Clinical Translational Science Award (Irving Scholar Award: GRS) grant: UL1TR001873, and Private Donor funds to Reyes-Soffer. WHICAP Data collection and sharing for this project was supported by the National Institutes on Aging (NIA) of the National Institutes of Health (NIH): R01AG072474, AG066107, AG059013 and RF1AG054023 to Dr. Richard Mayeux.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The use of the WHICAP cohort (#AAAO9804) and additional studies presented here (#AAAV0773) are approved by the institutional review board of Columbia University, New York City.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll the data is available on a server and by request from study senior author. https://github.com/alexliyihao/vntrwrap https://github.com/alexliyihao/lpa-analysis WHICAPWashington Heights Inwood Community Aging ProjectLp(a)Lipoprotein (a)wISweighted Isoform SizeASCVDAtherosclerotic Cardiovascular Disease